- Home
- NVRO vs ACIU Comparison
NVRO vs ACIU Comparison
Compare NVRO & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVRO
- ACIU
- Stock Information
- Founded
- NVRO 2006
- ACIU 2003
- Country
- NVRO United States
- ACIU Switzerland
- Employees
- NVRO N/A
- ACIU N/A
- Industry
- NVRO Medical/Dental Instruments
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- NVRO Health Care
- ACIU Health Care
- Exchange
- NVRO Nasdaq
- ACIU Nasdaq
- Market Cap
- NVRO 221.2M
- ACIU 247.4M
- IPO Year
- NVRO 2014
- ACIU 2016
- Fundamental
- Price
- NVRO $5.84
- ACIU $1.66
- Analyst Decision
- NVRO Hold
- ACIU Strong Buy
- Analyst Count
- NVRO 12
- ACIU 2
- Target Price
- NVRO $7.24
- ACIU $12.00
- AVG Volume (30 Days)
- NVRO 1.2M
- ACIU 185.3K
- Earning Date
- NVRO 05-06-2025
- ACIU 05-12-2025
- Dividend Yield
- NVRO N/A
- ACIU N/A
- EPS Growth
- NVRO N/A
- ACIU N/A
- EPS
- NVRO N/A
- ACIU N/A
- Revenue
- NVRO $408,518,000.00
- ACIU $30,136,397.00
- Revenue This Year
- NVRO $1.54
- ACIU N/A
- Revenue Next Year
- NVRO $4.37
- ACIU $680.74
- P/E Ratio
- NVRO N/A
- ACIU N/A
- Revenue Growth
- NVRO N/A
- ACIU 84.51
- 52 Week Low
- NVRO $3.17
- ACIU $1.77
- 52 Week High
- NVRO $13.84
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- NVRO 3.08
- ACIU 22.91
- Support Level
- NVRO $5.83
- ACIU $1.77
- Resistance Level
- NVRO $5.86
- ACIU $2.05
- Average True Range (ATR)
- NVRO 0.02
- ACIU 0.11
- MACD
- NVRO -0.39
- ACIU -0.03
- Stochastic Oscillator
- NVRO 0.00
- ACIU 0.00
About NVRO Nevro Corp.
Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.